Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Lambert JM, Morris CQ.

Adv Ther. 2017 May;34(5):1015-1035. doi: 10.1007/s12325-017-0519-6. Epub 2017 Mar 30. Review.

2.

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.

Fedele R, Martino M, Recchia AG, Irrera G, Gentile M, Morabito F.

J Immunol Res. 2015;2015:968212. doi: 10.1155/2015/968212. Epub 2015 Dec 16. Review.

3.

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Kim EG, Kim KM.

Biomol Ther (Seoul). 2015 Nov;23(6):493-509. doi: 10.4062/biomolther.2015.116. Epub 2015 Nov 1. Review.

4.

Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.

Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R.

J Clin Oncol. 2015 Nov 10;33(32):3759-65. doi: 10.1200/JCO.2014.60.3787. Epub 2015 Aug 10.

5.

Anaplastic large-cell lymphoma in AIDS.

Krol ML, Podduturi V, Majid-Moosa A, Krause JR, Mora A Jr.

Proc (Bayl Univ Med Cent). 2015 Jul;28(3):378-80.

6.

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.

Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST.

Onco Targets Ther. 2014 Dec 3;7:2227-36. doi: 10.2147/OTT.S46887. eCollection 2014. Review.

7.

The development of potential antibody-based therapies for myeloma.

Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B.

Blood Rev. 2015 Mar;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub 2014 Sep 28. Review.

8.

Relapsed Hodgkin lymphoma: management strategies.

Montanari F, Diefenbach C.

Curr Hematol Malig Rep. 2014 Sep;9(3):284-93. doi: 10.1007/s11899-014-0220-7. Review.

9.

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

Siddiqi T, Thomas SH, Chen R.

Pharmgenomics Pers Med. 2014 Feb 20;7:79-85. doi: 10.2147/PGPM.S57700. eCollection 2014. Review.

10.

Advances in the treatment of hematologic malignancies using immunoconjugates.

Palanca-Wessels MC, Press OW.

Blood. 2014 Apr 10;123(15):2293-301. doi: 10.1182/blood-2013-10-492223. Epub 2014 Feb 27. Review.

11.

Brentuximab Vedotin in CD30+ Lymphomas.

Perini GF, Pro B.

Biol Ther. 2013;3:15-23. Epub 2013 Mar 1. Review.

12.

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Chen X, Soma LA, Fromm JR.

Onco Targets Ther. 2013 Dec 19;7:45-56. doi: 10.2147/OTT.S39107. Review.

13.

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Diefenbach C, Advani R.

Hematol Oncol Clin North Am. 2014 Feb;28(1):105-22. doi: 10.1016/j.hoc.2013.10.004. Review.

14.

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Mei M, Thomas S, Chen R.

BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7. Review.

15.

CD30: from basic research to cancer therapy.

Muta H, Podack ER.

Immunol Res. 2013 Dec;57(1-3):151-8. Review.

17.

Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.

Chao MP.

Cancer Manag Res. 2013 Aug 23;5:251-69. doi: 10.2147/CMAR.S34273. eCollection 2013. Review.

18.

Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.

Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, Chu Q, Lavasanifar A, Lai R.

Biomaterials. 2013 Nov;34(34):8718-8725. doi: 10.1016/j.biomaterials.2013.07.068. Epub 2013 Aug 12.

19.

Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.

Chhim RF, Shelton CM, Christensen ML.

J Pediatr Pharmacol Ther. 2013 Jan;18(1):14-38. doi: 10.5863/1551-6776-18.1.14.

20.

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Vaklavas C, Forero-Torres A.

Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.

Supplemental Content

Support Center